Jump Financial LLC Invests $688,000 in Perspective Therapeutics, Inc. (NYSE:CATX)

Jump Financial LLC acquired a new position in Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 215,725 shares of the company's stock, valued at approximately $688,000. Jump Financial LLC owned about 0.32% of Perspective Therapeutics at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the stock. Rhumbline Advisers raised its position in Perspective Therapeutics by 4.5% in the 4th quarter. Rhumbline Advisers now owns 94,992 shares of the company's stock worth $303,000 after purchasing an additional 4,075 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Perspective Therapeutics by 3.4% during the 4th quarter. Bank of New York Mellon Corp now owns 143,469 shares of the company's stock worth $458,000 after acquiring an additional 4,693 shares during the period. JPMorgan Chase & Co. grew its holdings in Perspective Therapeutics by 24.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 24,912 shares of the company's stock worth $333,000 after acquiring an additional 4,844 shares during the period. Trueblood Wealth Management LLC grew its holdings in Perspective Therapeutics by 37.0% during the 4th quarter. Trueblood Wealth Management LLC now owns 22,236 shares of the company's stock worth $71,000 after acquiring an additional 6,000 shares during the period. Finally, Nicholson Wealth Management Group LLC grew its holdings in Perspective Therapeutics by 0.4% during the 4th quarter. Nicholson Wealth Management Group LLC now owns 1,609,283 shares of the company's stock worth $5,134,000 after acquiring an additional 7,000 shares during the period. Institutional investors own 54.66% of the company's stock.

Perspective Therapeutics Stock Up 2.5 %

Perspective Therapeutics stock traded up $0.06 during midday trading on Monday, reaching $2.45. The stock had a trading volume of 425,463 shares, compared to its average volume of 1,026,766. The firm's fifty day simple moving average is $2.30 and its 200-day simple moving average is $4.54. Perspective Therapeutics, Inc. has a 1-year low of $1.60 and a 1-year high of $19.05.

Insider Activity at Perspective Therapeutics

In related news, Director Robert F. Williamson III purchased 38,145 shares of the stock in a transaction on Monday, March 31st. The shares were purchased at an average price of $2.14 per share, with a total value of $81,630.30. Following the transaction, the director now directly owns 108,982 shares of the company's stock, valued at $233,221.48. This trade represents a 53.85 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Johan M. Spoor bought 22,026 shares of Perspective Therapeutics stock in a transaction dated Friday, March 28th. The shares were acquired at an average price of $2.24 per share, with a total value of $49,338.24. Following the completion of the purchase, the chief executive officer now directly owns 59,383 shares in the company, valued at $133,017.92. This trade represents a 58.96 % increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 115,696 shares of company stock valued at $256,344. 3.52% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts have commented on CATX shares. Cantor Fitzgerald raised shares of Perspective Therapeutics to a "strong-buy" rating in a report on Tuesday, March 4th. Brookline Capital Management raised shares of Perspective Therapeutics to a "strong-buy" rating in a report on Monday, March 10th. Scotiabank started coverage on shares of Perspective Therapeutics in a report on Friday, March 7th. They issued a "sector outperform" rating and a $15.00 price target for the company. Lifesci Capital raised shares of Perspective Therapeutics to a "strong-buy" rating in a report on Thursday, March 6th. Finally, HC Wainwright reissued a "buy" rating and issued a $10.00 price target on shares of Perspective Therapeutics in a report on Monday, March 31st. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Perspective Therapeutics currently has a consensus rating of "Buy" and an average price target of $12.75.

Perspective Therapeutics Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.